Nasdaq

Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer

MADISON, Wis., Oct. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, ...
Nasdaq

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

- RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease RxPONDER showed a different effect of ...
Seeking Alpha

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

New data supports the value of the Oncotype DX Breast Recurrence Score ® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally MADISON, Wis.-- ...
Seeking Alpha

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
Business Insider

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer

New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...
News Medical

Oncotype DX Breast Recurrence Score test recommended by NICE for lymph node-positive breast cancer patients

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
Business Insider

Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients

REDWOOD CITY, Calif., Feb. 5, 2019 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from a multi-center, prospective validation study of the Oncotype DX ® ...
EurekAlert!

EndoPredict outperforms Oncotype Dx in predicting the risk breast cancer recurrence

Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak, Ph.D. Date: Friday, Dec.9, 2016: 4:15 p.m. CT. Location: S6-05; General Session 6 - ...
Insurancenewsnet.com

Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in ...

SAN DIEGO and REDWOOD CITY, Calif., March 30, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative ...
The American Journal of Managed Care

Oncotype DX to be Included in NIH's Genetic Testing Registry

(NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests.
CNN

Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate ...

SAN DIEGO and REDWOOD CITY, Calif., Oct. 29, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative ...